Why cold agglutinin disease is a complement disease before it is a hemolytic one
Note: The video and audio linked above were generated with the assistance of AI. Clinical accuracy has been reviewed, but no AI-generated content can be guaranteed to be fully error-free.
Cold agglutinin disease is fundamentally a disorder of classical complement activation. The antibody initiates the process, but complement determines the phenotype.1
Understanding CAD requires shifting focus away from antibody binding alone and toward the kinetics, amplification, regulation, and downstream consequences of complement activation, particularly at the level of C1 and C3. This is why CAD behaves differently from warm autoimmune hemolytic anemia, why corticosteroids fail, and why proximal complement inhibition is uniquely effective.2
This spoke explains how complement biology shapes hemolysis, symptoms, and therapeutic vulnerability in CAD.3
The initiating event: IgM and C1 engagement
In primary CAD, the pathogenic antibody is almost always IgM.4
IgM is far more efficient at complement activation than IgG because a single pentameric IgM molecule presents multiple Fc regions in close proximity, allowing strong C1q engagement. In contrast, IgG molecules must cluster densely on the red-cell surface to achieve comparable activation. This structural difference explains why relatively small amounts of IgM can trigger robust complement activation.
When bound to red blood cells, pentameric IgM undergoes a conformational change that exposes binding sites for C1q, triggering complement activation even at relatively low antibody densities.5
Key features:6
- IgM binds red cells most efficiently at lower temperatures
- C1q binding activates C1r and C1s
- Complement activation proceeds rapidly once initiated and may continue after antibody disengagement.
- Antibody quantity matters less than thermal amplitude and complement-fixing efficiency
The antibody acts as a switch. Complement supplies the force.7
Classical pathway dominance in CAD
Complement activation in CAD proceeds almost exclusively through the classical pathway.8
This has several consequences:9
alternative and lectin pathways are not primary drivers
C1 activation is the critical upstream event
downstream amplification depends on intact C3 convertase formation
Once C1s is activated, it cleaves C4 and C2, forming the classical C3 convertase (C4b2a). This step commits the system to amplification.10
At this point, complement activation becomes self-propagating, even if antibody binding is transient.11
Because C4 is consumed early in classical pathway activation, patients with active CAD often show disproportionately low C4 levels compared with C3. This pattern reflects classical pathway engagement rather than generalized complement depletion and can serve as a biomarker of ongoing disease activity.
C3 as the central effector molecule
The dominant biologic event in CAD is C3 activation and deposition, not terminal complement lysis.12
After C3 convertase formation:13
- C3 is cleaved into C3a and C3b
- C3b covalently deposits on the red cell surface
- red cells become opsonized for clearance
Most hemolysis in CAD is therefore:14
- extravascular, mediated by macrophages in the liver
- driven by C3b and iC3b recognition
- largely independent of membrane attack complex formation
This explains why:15
- hemolysis can be chronic and compensated
- LDH and bilirubin elevations may be modest
- haptoglobin may be low but not absent
CAD is a disease of opsonization, not explosive lysis.
Surface-bound C3b is progressively cleaved during circulation to iC3b and then to C3d. Earlier fragments promote macrophage recognition and clearance, whereas C3d represents a more stable remnant that persists on surviving cells. This processing explains why the DAT in CAD typically detects C3d rather than C3b and why complement positivity may remain even when hemolysis is clinically improving.
Once initial C3b is deposited through classical pathway activation, it can recruit factor B and factor D to form an alternative pathway amplification loop, generating additional C3 convertase and further opsonization. Thus, transient antibody binding can initiate a cascade that amplifies independently of continued classical pathway signaling.
The “hit-and-run” nature of complement in CAD
A defining feature of CAD is that complement activation often continues after antibody disengagement.16
This occurs because:17
- IgM binds transiently at cooler peripheral temperatures
- complement activation persists as blood returns to central circulation
- C3b remains fixed to the red cell surface
As a result:18
- hemolysis can continue after rewarming
- disease activity may persist despite cold avoidance
- symptoms do not correlate tightly with measured antibody binding
Complement activation has memory. The antibody does not need to remain bound.
Why intravascular hemolysis is limited
Although terminal complement activation can occur, MAC-mediated intravascular hemolysis is usually limited in CAD.19
Reasons include:20
- efficient regulation of terminal complement on red cells
- rapid clearance of opsonized cells before MAC formation
- predominant C3-mediated extravascular removal
However:21
- severe disease or high complement activity can overwhelm regulation
- intravascular hemolysis may occur during acute exacerbations
- complement inhibition upstream prevents both pathways
This balance explains variability in laboratory severity across patients.
Red cells are normally protected from terminal complement injury by membrane regulatory proteins, especially CD55 (decay-accelerating factor) and CD59, which respectively disrupt convertase formation and prevent membrane attack complex assembly. Because these regulators are intact in CAD, terminal complement activation is usually contained before intravascular lysis occurs. Only when complement activation is unusually intense can regulatory capacity be exceeded, allowing intravascular hemolysis to emerge.
Complement and symptoms beyond anemia
Complement activation contributes to symptoms that are not explained by hemoglobin alone.22
Potential mechanisms include:
- release of anaphylatoxins (C3a, C5a)
- endothelial activation
- microvascular dysfunction
- inflammation and fatigue
These effects help explain:23
- fatigue out of proportion to anemia
- cold-induced pain and circulatory symptoms
- patient-reported burden exceeding laboratory expectations
CAD is not just a red cell clearance problem. It is a systemic complement-mediated state.
Why corticosteroids fail
Steroids are ineffective in CAD because they target the wrong biology.24
Corticosteroids:
- suppress Fc-mediated immune clearance
- reduce IgG-driven inflammation
- have little impact on complement activation
In CAD:25
- hemolysis is complement-driven
- antibody production is clonal and steroid-resistant
- macrophage clearance is complement-opsonin mediated
Steroids do not meaningfully interrupt the disease pathway.
Therapeutic implications of complement biology
Complement biology explains the success of proximal complement inhibition in CAD.
Targeting C1s:26
- blocks classical pathway initiation
- prevents downstream C3 deposition
- halts hemolysis without broad immunosuppression
This approach:
- acts upstream of amplification
- preserves alternative pathway function
- aligns precisely with CAD pathophysiology
Complement inhibition works not because CAD is severe, but because it is mechanistically clean.
Explicit principle
In CAD, the antibody initiates disease, but complement determines phenotype.27
Severity, chronicity, symptoms, and treatment response are shaped less by how much antibody is present than by how efficiently complement is activated and sustained.28
Understanding complement biology is therefore not optional. It is the key to understanding why CAD behaves the way it does — and why it responds to the therapies that work.
Reflect and Apply
A patient with CAD has low C4 and modestly low C3.
Explain this pattern mechanistically.
Test your thinking
A short, judgment-focused quiz on complement biology in cold agglutinin disease.